• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受持续静静脉血液滤过治疗的重症患者中的胱抑素C

Cystatin C in critically ill patients treated with continuous venovenous hemofiltration.

作者信息

Baas Marije C, Bouman Catherine S C, Hoek Frans J, Krediet Raymond T, Schultz Marcus J

机构信息

Department of Intensive Care Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

出版信息

Hemodial Int. 2006 Oct;10 Suppl 2:S33-7. doi: 10.1111/j.1542-4758.2006.00115.x.

DOI:10.1111/j.1542-4758.2006.00115.x
PMID:17022749
Abstract

Assessment of residual renal function in critically ill patients with acute renal failure (ARF) treated with continuous venovenous hemofiltration (CVVH) is difficult. Cystatin C (CysC) is a low-molecular-weight protein (13.3 kDa) removed from the body by glomerular filtration. Its serum concentration has been advocated for assessment of renal function in patients with kidney disease. To investigate whether the removal of CysC by CVVH is likely to influence its serum concentration, concentrations of CysC were measured in 3 consecutive samples in 18 patients with oliguric ARF treated with CVVH (2 L/hr). Samples were taken from the afferent and efferent blood lines and from the ultrafiltrate line. Concentrations of CysC did not change during the time interval studied. The mean serum concentrations of CysC were 2.25+/-0.45 mg/L in the afferent and 2.19+/-0.56 mg/L in the efferent samples (NS); ultrafiltrate concentrations of CysC were 1.01+/-0.45 mg/L. The sieving coefficient of CysC was 0.52+/-0.20; the clearance of CysC was 17.3+/-6.6 mL/min; and the quantity of CysC removed averaged 2.13 mg/hr. During CVVH (2 L/hr), the quantity of CysC removed is less than 30% of its production and no rapid changes in its serum concentration are observed. Therefore, CVVH (2 L/hr) is unlikely to influence serum concentrations of CysC significantly, which suggests that it can be used to monitor residual renal function during CVVH.

摘要

评估接受连续性静脉-静脉血液滤过(CVVH)治疗的急性肾衰竭(ARF)危重症患者的残余肾功能很困难。胱抑素C(CysC)是一种低分子量蛋白质(13.3 kDa),通过肾小球滤过从体内清除。其血清浓度已被推荐用于评估肾病患者的肾功能。为了研究CVVH对CysC的清除是否可能影响其血清浓度,对18例接受CVVH(2 L/小时)治疗的少尿型ARF患者的3个连续样本进行了CysC浓度测定。样本取自输入和输出血路以及超滤液管路。在研究的时间间隔内,CysC浓度没有变化。输入样本中CysC的平均血清浓度为2.25±0.45 mg/L,输出样本中为2.19±0.56 mg/L(无显著性差异);CysC的超滤液浓度为1.01±0.45 mg/L。CysC的筛滤系数为0.52±0.20;CysC的清除率为17.3±6.6 mL/分钟;CysC的平均清除量为2.13 mg/小时。在CVVH(2 L/小时)期间,CysC的清除量小于其生成量的30%,且未观察到其血清浓度有快速变化。因此,CVVH(2 L/小时)不太可能显著影响CysC的血清浓度,这表明它可用于监测CVVH期间的残余肾功能。

相似文献

1
Cystatin C in critically ill patients treated with continuous venovenous hemofiltration.接受持续静静脉血液滤过治疗的重症患者中的胱抑素C
Hemodial Int. 2006 Oct;10 Suppl 2:S33-7. doi: 10.1111/j.1542-4758.2006.00115.x.
2
[Cystatin C as estimator of glomerular filtration rate in patients with advanced chronic renal disease].[胱抑素C作为晚期慢性肾病患者肾小球滤过率的评估指标]
Nefrologia. 2006;26(4):433-8.
3
Serum cystatin C concentration as a marker of acute renal dysfunction in critically ill patients.血清胱抑素C浓度作为危重症患者急性肾功能障碍的标志物。
Crit Care. 2005 Apr;9(2):R139-43. doi: 10.1186/cc3044. Epub 2005 Feb 7.
4
Effect of filtration volume of continuous venovenous hemofiltration in the treatment of patients with acute renal failure in intensive care units.持续静静脉血液滤过的滤过 volume 在重症监护病房急性肾衰竭患者治疗中的作用 。 注:这里原文中的“filtration volume”直译为“滤过体积”,在医学语境中可能有更专业准确的表述,比如“滤过量”等,你可根据实际情况进一步优化。
Crit Care Med. 2003 Mar;31(3):841-6. doi: 10.1097/01.CCM.0000054866.45509.D0.
5
Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.美罗培南在接受持续静静脉血液滤过的急性肾衰竭重症患者中的药代动力学
Clin Pharmacol Ther. 1999 Jan;65(1):50-7. doi: 10.1016/S0009-9236(99)70121-9.
6
Cystatin C as a marker of residual renal function during continuous hemodiafiltration.胱抑素C作为持续血液透析滤过期间残余肾功能的标志物。
Kidney Blood Press Res. 2005;28(1):14-9. doi: 10.1159/000080936. Epub 2004 Sep 20.
7
Metabolic effects of continuous veno-venous haemofiltration in critically ill patients.连续性静脉-静脉血液滤过对危重症患者的代谢影响
Clin Intensive Care. 1994;5(6):293-5.
8
Estimation of residual glomerular filtration rate in dialysis patients from the plasma cystatin C level.根据血浆胱抑素C水平估算透析患者的残余肾小球滤过率。
Nephrol Dial Transplant. 2007 Jun;22(6):1633-8. doi: 10.1093/ndt/gfm027. Epub 2007 Apr 1.
9
Cystatin C as marker of residual renal function in patients on peritoneal dialysis: relation with parameters of peritoneal function.胱抑素C作为腹膜透析患者残余肾功能的标志物:与腹膜功能参数的关系。
J Nephrol. 2007 Jul-Aug;20(4):468-73.
10
Tumor necrosis factor-alpha during continuous high-flux hemodialysis in sepsis with acute renal failure.脓毒症合并急性肾衰竭患者持续高通量血液透析期间的肿瘤坏死因子-α
Kidney Int Suppl. 1999 Nov(72):S84-7.

引用本文的文献

1
Current role of biomarkers in the initiation and weaning of kidney replacement therapy in acute kidney injury.生物标志物在急性肾损伤肾脏替代治疗启动及撤机中的当前作用
World J Nephrol. 2025 Mar 25;14(1):99802. doi: 10.5527/wjn.v14.i1.99802.
2
Population pharmacokinetics of colistin sulfate in patients on continuous veno-venous hemodiafiltration.硫酸黏菌素在接受持续静静脉血液透析滤过治疗患者中的群体药代动力学
Sci Prog. 2025 Jan-Mar;108(1):368504251325334. doi: 10.1177/00368504251325334.
3
Cystatin C and Kidney Function Recovery in Patients Requiring Continuous KRT for Acute Kidney Injury.
急性肾损伤需要持续肾脏替代治疗患者的胱抑素C与肾功能恢复
Clin J Am Soc Nephrol. 2024 Nov 1;19(11):1395-1404. doi: 10.2215/CJN.0000000000000531. Epub 2024 Aug 21.
4
Optimal indicator for changing the filter during the continuous renal replacement therapy in intensive care unit patients with acute kidney injury: A crossover randomized trial.重症监护病房急性肾损伤患者持续肾脏替代治疗期间更换滤器的最佳指标:一项交叉随机试验。
World J Emerg Med. 2022;13(3):196-201. doi: 10.5847/wjem.j.1920-8642.2022.046.
5
Serum Cystatin C Does Not Predict Mortality or Treatment Failure in Peritoneal Dialysis: A Prospective Study.血清胱抑素C不能预测腹膜透析患者的死亡率或治疗失败:一项前瞻性研究。
Perit Dial Int. 2016 Jan-Feb;36(1):94-100. doi: 10.3747/pdi.2014.00071. Epub 2014 Sep 2.
6
Comparison of serum creatinine and serum cystatin C as biomarkers to detect sepsis-induced acute kidney injury and to predict mortality in CD-1 mice.比较血清肌酐和血清胱抑素C作为生物标志物在检测脓毒症诱导的急性肾损伤及预测CD-1小鼠死亡率中的作用
Am J Physiol Renal Physiol. 2014 Oct 15;307(8):F939-48. doi: 10.1152/ajprenal.00025.2013. Epub 2014 Aug 20.
7
Insufficient performance of serum cystatin C as a biomarker for acute kidney injury of postrenal etiology.血清胱抑素C作为肾后性病因急性肾损伤生物标志物的性能不足。
Intensive Care Med. 2012 Jan;38(1):170-1. doi: 10.1007/s00134-011-2384-0. Epub 2011 Oct 1.
8
Cystatin C is not a reliable marker of residual glomerular filtration rate during continuous renal replacement therapy.胱抑素C并非连续性肾脏替代治疗期间残余肾小球滤过率的可靠标志物。
Intensive Care Med. 2011 Nov;37(11):1893-4; author reply 1897-8. doi: 10.1007/s00134-011-2346-6. Epub 2011 Aug 18.
9
Biomarkers of acute kidney injury.急性肾损伤的生物标志物
Adv Chronic Kidney Dis. 2008 Jul;15(3):222-34. doi: 10.1053/j.ackd.2008.04.003.